Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bevacizumab
/ administration & dosage
Brain
/ diagnostic imaging
Brain Neoplasms
/ drug therapy
Combined Modality Therapy
Disease-Free Survival
Female
Glioblastoma
/ drug therapy
Humans
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Methylation
Radiation Dose Hypofractionation
Retrospective Studies
Temozolomide
/ administration & dosage
Treatment Outcome
Bevacizumab
Elderly glioblastoma
Hypofractionated radiotherapy
Temozolomide
Vulnerability
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
06
06
2019
accepted:
02
10
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
29
4
2020
Statut:
epublish
Résumé
The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (TMZ/Bev). Between October 2007 and August 2018, 30 patients with GBM aged ≥75 years were treated with hypofractionated radiotherapy consisting of 45 Gy in 15 fractions. Twenty patients received TMZ and 10 received TMZ/Bev as upfront chemotherapy. O-6-methylguanine DNA methyltransferase (MGMT) promoter methylation status was analyzed by pyrosequencing. The cutoff value of the mean level of methylation at the 16 CpG sites was 16%. Median overall survival (OS) and progression-free survival (PFS) were 12.9 months and 9.9 months, respectively. The 1-year OS and PFS rates were 64.7 and 34.7%, respectively. Median OS and PFS did not differ significantly between patients with MGMT promoter hypermethylation (N = 11) and those with hypomethylation (N = 16) (17.4 vs. 11.8 months, p = 0.32; and 13.1 vs. 7.3 months, p = 0.11, respectively). The median OS and PFS were not significantly different between TMZ (N = 20) and TMZ/Bev (N = 10) chemotherapy (median OS: TMZ 12.9 months vs. TMZ/Bev 14.6 months, p = 0.93, median PFS: TMZ 8.5 months vs TMZ/Bev 10.0 months, p = 0.64, respectively). The median time until Karnofsky performance status (KPS) score decreasing below 60 points was 7.9 months. The best radiological responses included 11 patients with a partial response (36.7%). Grade 3/4 toxicities included leukopenia in 15 patients (50%), anorexia in 4 (13.3%), and hyponatremia during concomitant chemotherapy in 3 (10%). Our hypofractionated radiotherapy regimen combined with TMZ or TMZ/Bev showed benefits in terms of OS, PFS, and KPS maintenance with acceptable toxicities in elderly patients with GBM aged ≥75 years.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (TMZ/Bev).
MATERIALS AND METHODS
METHODS
Between October 2007 and August 2018, 30 patients with GBM aged ≥75 years were treated with hypofractionated radiotherapy consisting of 45 Gy in 15 fractions. Twenty patients received TMZ and 10 received TMZ/Bev as upfront chemotherapy. O-6-methylguanine DNA methyltransferase (MGMT) promoter methylation status was analyzed by pyrosequencing. The cutoff value of the mean level of methylation at the 16 CpG sites was 16%.
RESULTS
RESULTS
Median overall survival (OS) and progression-free survival (PFS) were 12.9 months and 9.9 months, respectively. The 1-year OS and PFS rates were 64.7 and 34.7%, respectively. Median OS and PFS did not differ significantly between patients with MGMT promoter hypermethylation (N = 11) and those with hypomethylation (N = 16) (17.4 vs. 11.8 months, p = 0.32; and 13.1 vs. 7.3 months, p = 0.11, respectively). The median OS and PFS were not significantly different between TMZ (N = 20) and TMZ/Bev (N = 10) chemotherapy (median OS: TMZ 12.9 months vs. TMZ/Bev 14.6 months, p = 0.93, median PFS: TMZ 8.5 months vs TMZ/Bev 10.0 months, p = 0.64, respectively). The median time until Karnofsky performance status (KPS) score decreasing below 60 points was 7.9 months. The best radiological responses included 11 patients with a partial response (36.7%). Grade 3/4 toxicities included leukopenia in 15 patients (50%), anorexia in 4 (13.3%), and hyponatremia during concomitant chemotherapy in 3 (10%).
CONCLUSION
CONCLUSIONS
Our hypofractionated radiotherapy regimen combined with TMZ or TMZ/Bev showed benefits in terms of OS, PFS, and KPS maintenance with acceptable toxicities in elderly patients with GBM aged ≥75 years.
Identifiants
pubmed: 31718669
doi: 10.1186/s13014-019-1389-7
pii: 10.1186/s13014-019-1389-7
pmc: PMC6852964
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Bevacizumab
2S9ZZM9Q9V
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
200Références
Sci Rep. 2016 Mar 04;6:22477
pubmed: 26940435
Int J Clin Oncol. 2015 Feb;20(1):21-8
pubmed: 24705988
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):802-810
pubmed: 28602411
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):93-9
pubmed: 22079725
Radiother Oncol. 2010 Dec;97(3):361-9
pubmed: 20926149
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800
pubmed: 24495592
J Clin Oncol. 2015 Dec 10;33(35):4145-50
pubmed: 26392096
J Neurooncol. 2014 Jan;116(2):299-306
pubmed: 24173683
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):100-7
pubmed: 11516858
J Neurooncol. 2015 Nov;125(2):359-67
pubmed: 26423801
Neurol Med Chir (Tokyo). 2014;54(4):272-9
pubmed: 24257502
Radiat Oncol. 2017 Dec 6;12(1):197
pubmed: 29212499
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
Acta Neuropathol. 2013 Aug;126(2):267-76
pubmed: 23764841
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Neurol Med Chir (Tokyo). 2017;57(Suppl 1):9-102
pubmed: 28420810
Br J Radiol. 2012 Sep;85(1017):e770-81
pubmed: 22919020
J Neurooncol. 2011 Apr;102(2):247-53
pubmed: 20640480
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
Cancers (Basel). 2019 Mar 08;11(3):null
pubmed: 30857221
J Neurosurg. 2016 Apr;124(4):998-1007
pubmed: 26452121
J Clin Oncol. 2017 Jan 20;35(3):361-369
pubmed: 27893327
Cancer Treat Rev. 2013 Jun;39(4):350-7
pubmed: 22722053
Neurology. 2009 Apr 7;72(14):1217-22
pubmed: 19349600
N Engl J Med. 2007 Apr 12;356(15):1527-35
pubmed: 17429084
Int J Clin Oncol. 2018 Oct;23(5):820-825
pubmed: 29796740
Perm J. 2015 Winter;19(1):15-20
pubmed: 25663202
J Neurooncol. 2009 Jan;91(1):95-100
pubmed: 18758912
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neurooncol Pract. 2018 Nov;5(4):251-261
pubmed: 31385957
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Clin Oncol. 2004 May 1;22(9):1583-8
pubmed: 15051755
Int J Clin Oncol. 2016 Dec;21(6):1023-1029
pubmed: 27384182
Brain Tumor Pathol. 2015 Jan;32(1):22-30
pubmed: 24748374
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
ESMO Open. 2019 Jun 17;4(Suppl 2):e000520
pubmed: 31297242